A Randomized, Multicenter, 3-arm, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of SAR439794 in Peanut Allergic Adult and Adolescent Patients

Trial Profile

A Randomized, Multicenter, 3-arm, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of SAR439794 in Peanut Allergic Adult and Adolescent Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2018

At a glance

  • Drugs SAR 439794 (Primary) ; Glycopyranosyl lipid adjuvant
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 18 May 2018 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2019.
    • 07 May 2018 Status changed from not yet recruiting to recruiting.
    • 27 Apr 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top